MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202621064483 A) filed by Smita Kalyanrao Shejul on May 21, 2026, for Novel Fused Nitrogen–sulfur Heterocyclic Derivatives, Their Green Synthetic Processes, Pharmaceutical Compositions, And Dual Antimicrobial And Anticancer Applications.
Inventor includes Smita Kalyanrao Shejul.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: [068] The present invention relates to novel fused nitrogen–sulfur heterocyclic derivatives, environmentally sustainable synthetic methods for preparing the derivatives, pharmaceutical compositions containing the synthesized compounds, and their dual antimicrobial and anticancer applications. The disclosed invention provides structurally engineered fused heterocyclic frameworks comprising nitrogen-containing and sulfur-containing ring systems functionalized with biologically active substituents to enhance therapeutic efficacy, molecular stability, and target specificity. The compounds are synthesized using green chemistry approaches including microwave-assisted synthesis, solvent-free mechanochemical reactions, ultrasound-assisted cyclization, recyclable nanocatalysts, and biodegradable solvent systems, thereby reducing hazardous waste generation, energy consumption, and reaction time while improving overall product yield and scalability. The synthesized derivatives exhibit broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, multidrug-resistant microbial strains, and fungal pathogens through mechanisms involving membrane disruption, enzyme inhibition, oxidative stress induction, and nucleic acid interference. The compounds additionally demonstrate significant anticancer activity against multiple human cancer cell lines by inducing apoptosis, inhibiting cellular proliferation pathways, suppressing angiogenesis, generating reactive oxygen species, and modulating intracellular signaling pathways. The invention further provides pharmaceutical compositions formulated as tablets, capsules, injectables, nanoparticles, liposomes, hydrogels, transdermal systems, and sustained-release drug delivery platforms for enhanced bioavailability and targeted therapeutic administration. The disclosed invention therefore provides an environmentally sustainable and therapeutically effective platform for next-generation multifunctional antimicrobial and anticancer pharmaceutical agents. Accompanied Drawing [FIGS. 1-2]
Disclaimer: Curated by HT Syndication.
